Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally described in companion animals as well. Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three companion animals have been treated in a three years period with this combination. Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations

The hair and nail manifestations of COVID-19

Emerging literature evidence shows that the manifestations of the coronavirus disease 2019 (COVID-19), which is the disease caused by SARS-CoV-2, encompass alterations of the pulmonary, cardiovascular, gastrointestinal and neurological system. Moreover, hematologic and dermatologic manifestations have been documented. The aim of this review is to summarize the dermatologic manifestations of COVID-19 involving the hair and nails in a narrative way. A total of 1136 patients have been reported to have de-novo hair loss following COVID-19. Notably, 958 patients experienced telogen effluvium (TE) (female/male ratio = 3,86:1), two female patients experienced anagen effluvium and 176 people had alopecia areata (female/male ratio of 19:3). Ten patients were reported to have ungual changes following the infection with the novel coronavirus: the individuals affected were 6 women and 4 men. COVID-19 can be associated to hair and ungual manifestations. This review summarizes the evidence regarding the hair and ungual manifestations of COVID-19, which could be harnessed to better understand the clinical implications and pathophysiology of this disease that has been burdening society globally since December 2019

Female genital mucosal lesions associated with COVID-19 vaccination. a brief review of the literature

Female genital mucosal lesions associated with COVID-19 vaccination: A brief review of the literatur

Severe palmar hyperkeratosis and hematochezia in COVID-19

No abstract availabl

Cutaneous Endothelial Dysfunction and Complement Deposition in COVID-19

Non

Cutaneous Endothelial Dysfunction and Complement Deposition in COVID-19

Non

Necrotic acral lesions and lung failure in a fatal case of COVID-19

Non

A primary-care interventional model on the diverticular disease: Searching for the optimal therapeutic schedule

Introduction In routine colonoscopy, diverticulosis is the most commonly found feature, but only a minority of these cases show symptoms of diverticular disease. From June 2014 to December 2014, we enrolled prospectively 178 patients affected by symptomatic uncomplicated diverticular disease (Male/Female = 0.47, mean age 71.7 ± 11.5 y, range 41 to 95 y) from 15 General Pratictioners patient files. All patients were symptomatic; in all cases, diagnosis was been confirmed by a colonoscopy performed at least 1 year before. Patients with acute diverticulitis were excluded. On the basis of the predominant symptoms (abdominal complaints or constipation), patients were addressed to 4 different therapeutic approaches using mesalamine, rifaximine, probiotics (in a consortium of different species of Lactobacillus and Bifidobacterium), and fibers (Plantago Ovata Husk). All treatments lasted 3 months. Results: Sixty-three patients were enrolled in group A (rifaximine), 43 in group A1 (rifaximine + fibers + probiotics), 23 in group B (mesalamine), and 31 in group B1 (mesalamine + fibers). Analysis of variance suggested a statistically significant difference (P < 0.003) among groups at the end of the observation period, with Groups A1 and B1 showing a higher number of bowel movement per week. Global linear measurement confirmed the role of treatment as a significant factor (F = 2.858; P = 0.039) associated with body mass index (F = 6.972; P < 0.009). Conclusions: In accordance with the baseline clinical presentation, the supplementation of fiber and/or probiotics is associated with a statistically significant improvement in the clinical pattern of symptoms in patients with diverticular disease in a primary-care/family physician setting

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: results from a multicenter study

none24Background: Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. Data on clinical and immunological features of gliptin-associated bullous pemphigoid (GABP) are controversial. Objective: This study aims to clinically and immunologically characterize a large cohort of GABP patients to get insight into the pathophysiology of this emerging drug-induced variant of BP. Methods: Seventy-four GABP patients were prospectively enrolled and characterized from nine different Italian Dermatology Units between 2013 and 2020. Results: Our findings demonstrate that in GABP patients: i) the non-inflammatory phenotype which is characterized by low amounts of circulating and skin infiltrating eosinophils is frequently found; ii) IgG, IgE and IgA humoral response to BP180 and BP230 antigens is reduced in frequency and titers when compared with idiopathic BP; iii) IgG reactivity targets multiple BP180 epitopes other than NC16A. Limitations: A limitation of the study is the control group that did not comprise only type 2 diabetes mellitus BP patients. Conclusions: GABP patients show peculiar features of anti-BP180 and -BP230 humoral response laying the foundations for diagnostic improvements and to get novel insights into understanding the mechanism of BP onset.noneSalemme, Adele; Fania, Luca; Scarabello, Alessandra; Caproni, Marzia; Marzano, Angelo Valerio; Cozzani, Emanuele; Feliciani, Claudio; De Simone, Clara; Papini, Manuela; Satta, Rosanna Rita; Parodi, Aurora; Mariotti, Feliciana; Lechiancole, Stefania; Genovese, Giovanni; Passarelli, Francesca; Festa, Francesca; Bellei, Barbara; Provini, Alessia; Donatella Sordi, null; Pallotta, Sabatino; Abeni, Damiano; Mazzanti, Cinzia; Didona, Biagio; Di Zenzo, GiovanniSalemme, Adele; Fania, Luca; Scarabello, Alessandra; Caproni, Marzia; Marzano, Angelo Valerio; Cozzani, Emanuele; Feliciani, Claudio; De Simone, Clara; Papini, Manuela; Satta, Rosanna Rita; Parodi, Aurora; Mariotti, Feliciana; Lechiancole, Stefania; Genovese, Giovanni; Passarelli, Francesca; Festa, Francesca; Bellei, Barbara; Provini, Alessia; Donatella Sordi, Null; Pallotta, Sabatino; Abeni, Damiano; Mazzanti, Cinzia; Didona, Biagio; Di Zenzo, Giovann